Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

0.8349 +0.0149 (+1.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Dow Surges 950 Points; S&P 500 Rises 3%
U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping around 950 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Stocks Stage Midday Comeback After Red-Hot CPI Data
The market is brushing off this morning's CPI data. 
Via Talk Markets
Why Is Axsome Therapeutics (AXSM) Stock Up Today?
Sometimes, company shares can catch a bid when a rival gets bad news. That's happening with Axsome today as AXSM stock moves higher. 
Via InvestorPlace
Gold Down 1.5%; Domino's Pizza Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 150 points on Thursday. 
Via Benzinga
Relmada Stock Tumbles To 52-Week Low On Failed Depression Trial
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
Why Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares jumped 89% to $0.4242 after dipping 34% on Wednesday. 
Via Benzinga
Why Are Tech Stocks Down Today?
Tech stocks aren't doing so hot on Thursday as investors react to the latest data from the Consumer Price Index (CPI) report for September. 
Via InvestorPlace
Progressive, Asana And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Is Relmada (RLMD) Stock Down 78% Today?
Relmada Therapeutics (RLMD) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial. 
Via InvestorPlace
Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges
The company noted "paradoxical results" where the placebo, at times, topped the drug. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares rose 24.6% to $0.14 during Thursday's pre-market session. The market value of their outstanding shares is at $17.1 million. 
Via Benzinga
Why Relmada Therapeutics Shares Are Trading Lower By 84%; Here Are 23 Stocks Moving Premarket
Gainers Laser Photonics Corporation (NASDAQ: LASE) shares rose 45% to $4.24 in pre-market trading. Laser Photonics announced that Coca-Cola recently completed the implementation of its first CleanTech... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
Today's depression drugs don't fit many patients' needs. Biotech companies may change that. 
Via Investor's Business Daily
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Relmada Secures FDA Fast Track Status For Depressive Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ: RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Exposures COVID-19
10 Biggest Price Target Changes For Monday
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading. 
Via Benzinga
Relmada Therapeutics Earnings Preview
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Here's Why Relmada Therapeutics Shares Are Rising
Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada... 
Via Benzinga
Earnings Scheduled For March 23, 2022
Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid... 
Via Benzinga
Relmada Therapeutics's Earnings Outlook
Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement.... 
Via Benzinga
Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential
Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD.... 
Via Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate
Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.